NASDAQ:MDGL Madrigal Pharmaceuticals Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Madrigal Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $77.35 +3.76 (+5.11%) (As of 07/5/2022 03:07 PM ET) Add Compare Share Today's Range$72.32▼$78.0150-Day Range$58.04▼$84.6552-Week Range$52.33▼$105.93Volume7,129 shsAverage Volume184,343 shsMarket Capitalization$1.32 billionP/E RatioN/ADividend YieldN/APrice Target$167.43 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Madrigal Pharmaceuticals MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside116.5% Upside$167.43 Price TargetShort InterestBearish13.38% of Float Sold ShortDividend StrengthN/ASustainability-1.11Upright™ Environmental ScoreNews Sentiment0.85Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($14.55) to ($11.17) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.2.31 out of 5 starsMedical Sector225th out of 1,428 stocksPharmaceutical Preparations Industry109th out of 680 stocks 3.5 Analyst's Opinion Consensus RatingMadrigal Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $167.43, Madrigal Pharmaceuticals has a forecasted upside of 116.5% from its current price of $77.35.Amount of Analyst CoverageMadrigal Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted13.38% of the float of Madrigal Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverMadrigal Pharmaceuticals has a short interest ratio ("days to cover") of 8.6.Change versus previous monthShort interest in Madrigal Pharmaceuticals has recently increased by 3.75%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldMadrigal Pharmaceuticals does not currently pay a dividend.Dividend GrowthMadrigal Pharmaceuticals does not have a long track record of dividend growth. Previous Next 3.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMadrigal Pharmaceuticals has received a 69.32% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physiological diseases " and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Madrigal Pharmaceuticals is -1.11. Previous Next 2.1 News and Social Media Coverage News SentimentMadrigal Pharmaceuticals has a news sentiment score of 0.85. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Madrigal Pharmaceuticals this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for MDGL on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Madrigal Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Madrigal Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders29.71% of the stock of Madrigal Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions81.83% of the stock of Madrigal Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Madrigal Pharmaceuticals are expected to grow in the coming year, from ($14.55) to ($11.17) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Madrigal Pharmaceuticals is -5.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Madrigal Pharmaceuticals is -5.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMadrigal Pharmaceuticals has a P/B Ratio of 6.74. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive MDGL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Madrigal Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address About Madrigal Pharmaceuticals (NASDAQ:MDGL) StockMadrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.Read More MDGL Stock News HeadlinesJune 30, 2022 | americanbankingnews.comAnalysts Set Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Price Target at $176.83June 29, 2022 | americanbankingnews.comMadrigal Pharmaceuticals (NASDAQ:MDGL) Shares Down 5.2% June 27, 2022 | nasdaq.comMDGL Crosses Below Key Moving Average LevelJune 27, 2022 | finance.yahoo.comAnalysts Believe Madrigal's Resmetirom Shows Impressive Overall Profile In Liver FibrosisJune 25, 2022 | finance.yahoo.comMadrigal Pharmaceuticals Presents Late-Breaking Phase 3 NASH Data and Multiple Oral Abstracts at EASL’s International Liver Congress™June 24, 2022 | americanbankingnews.comMadrigal Pharmaceuticals (NASDAQ:MDGL) Stock Price Up 8.3%June 6, 2022 | finance.yahoo.comMadrigal Pharmaceuticals Supports International NASH Day on June 9June 2, 2022 | finance.yahoo.comMadrigal Pharmaceuticals Announces Participation at Three Upcoming Investor ConferencesMay 17, 2022 | finance.yahoo.comMadrigal Pharmaceuticals Announces Participation at Two Upcoming Investor ConferencesMay 9, 2022 | seekingalpha.comMadrigal Pharmaceuticals, Inc. (MDGL) CEO Paul Friedman on Q1 2022 Results - Earnings Call TranscriptMay 9, 2022 | seekingalpha.comMadrigal Pharmaceuticals GAAP EPS of -$3.36 beats by $0.20May 9, 2022 | finance.yahoo.comMadrigal Pharmaceuticals Provides Clinical and Business Updates and Reports 2022 First Quarter Financial ResultsApril 28, 2022 | finance.yahoo.comMadrigal Pharmaceuticals to Announce First Quarter 2022 Financial Results and Provide Clinical and Business Updates on May 9April 19, 2022 | seekingalpha.comMadrigal: NASH Data In Q4 Is The KeyApril 18, 2022 | nasdaq.comMadrigal Pharmaceuticals Becomes Oversold (MDGL)April 12, 2022 | finance.yahoo.com10 Best Stocks to Buy Now According to Billionaire Nicholas Pritzker’s Tao CapitalApril 11, 2022 | nasdaq.comMadrigal Pharmaceuticals (MDGL) Shares Cross Below 200 DMAMarch 18, 2022 | nasdaq.comNotable Friday Option Activity: MDGL, ASAN, LLMarch 9, 2022 | finance.yahoo.comMadrigal Pharmaceuticals to Present at the Oppenheimer Healthcare ConferenceFebruary 24, 2022 | seekingalpha.comMadrigal Pharmaceuticals Q4 net loss widens Y/YFebruary 24, 2022 | finance.yahoo.comMadrigal Pharmaceuticals Provides Business and Clinical Updates and Reports 2021 Fourth Quarter and Full Year Financial ResultsFebruary 9, 2022 | nasdaq.comMDGL Makes Bullish Cross Above Critical Moving AverageJanuary 31, 2022 | reuters.comMadrigal's drug candidate reduces fatty liver in late-stage NASH trialJanuary 31, 2022 | finance.yahoo.comMadrigal Pharma's Kidney Disease Candidate Improves Liver, Cardiovascular HealthJanuary 31, 2022 | finance.yahoo.comMadrigal shares rise, market cap surpasses $1B on positive late-stage study results for lead drug candidateSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:MDGL CUSIP87162T20 CIK1157601 Webwww.madrigalpharma.com Phone(484) 380-9263Fax781-274-8228Employees71Year Founded2011Company Calendar Last Earnings5/09/2022Today7/05/2022Next Earnings (Estimated)8/04/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$167.43 High Stock Price Forecast$220.00 Low Stock Price Forecast$111.00 Forecasted Upside/Downside+116.5%Consensus RatingBuy Rating Score (0-4)3 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($14.65) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-241,850,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-116.51% Return on Assets-87.47% Debt Debt-to-Equity RatioN/A Current Ratio2.89 Quick Ratio2.89 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$11.47 per share Price / Book6.74Miscellaneous Outstanding Shares17,100,000Free Float12,022,000Market Cap$1.32 billion OptionableOptionable Beta1.20 Social Links Madrigal Pharmaceuticals Frequently Asked Questions Should I buy or sell Madrigal Pharmaceuticals stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Madrigal Pharmaceuticals in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Madrigal Pharmaceuticals stock. View analyst ratings for Madrigal Pharmaceuticals or view top-rated stocks. What is Madrigal Pharmaceuticals' stock price forecast for 2022? 6 equities research analysts have issued 12-month price objectives for Madrigal Pharmaceuticals' shares. Their MDGL stock forecasts range from $111.00 to $220.00. On average, they predict Madrigal Pharmaceuticals' share price to reach $167.43 in the next twelve months. This suggests a possible upside of 116.5% from the stock's current price. View analysts' price targets for Madrigal Pharmaceuticals or view top-rated stocks among Wall Street analysts. How has Madrigal Pharmaceuticals' stock performed in 2022? Madrigal Pharmaceuticals' stock was trading at $84.74 on January 1st, 2022. Since then, MDGL shares have decreased by 8.7% and is now trading at $77.35. View the best growth stocks for 2022 here. When is Madrigal Pharmaceuticals' next earnings date? Madrigal Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022. View our earnings forecast for Madrigal Pharmaceuticals. How were Madrigal Pharmaceuticals' earnings last quarter? Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) issued its quarterly earnings results on Monday, May, 9th. The biopharmaceutical company reported ($3.36) earnings per share for the quarter, beating analysts' consensus estimates of ($3.75) by $0.39. During the same period in the previous year, the company posted ($3.32) EPS. View Madrigal Pharmaceuticals' earnings history. Who are Madrigal Pharmaceuticals' key executives? Madrigal Pharmaceuticals' management team includes the following people: Dr. Paul A. Friedman M.D., Chairman & CEO (Age 79, Pay $1.05M)Dr. Rebecca A. Taub M.D., Founder, Chief Medical Officer, Pres of R&D and Director (Age 70, Pay $854.75k)Mr. Alex G. Howarth, Sr. VP & CFO (Age 53, Pay $605.3k)Mr. Brian J. Lynch J.D., Sr. VP & Gen. Counsel (Age 60, Pay $699.28k)Mr. Remy Sukhija, Sr. VP & Chief Commercial Officer (Age 50, Pay $720.07k)Dr. Kianoush Motesharei Ph.d., Sr. VP of Bus. & Corp. Devel. (Age 52)Mr. Edward Chiang, Sr. VP of Clinical & Technical OperationsMr. Thomas W. Hare, Sr. VP of Clinical ManagementDr. Robert E. Waltermire Ph.D., Chief Pharmaceutical Devel. Officer (Age 58)Dr. Stephen Dodge M.B.A., Pharm.D., Sr. VP of Global Medical Affairs Who are some of Madrigal Pharmaceuticals' key competitors? Some companies that are related to Madrigal Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Seagen (SGEN), Biogen (BIIB), Alnylam Pharmaceuticals (ALNY), Incyte (INCY), BioMarin Pharmaceutical (BMRN), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Repligen (RGEN), Exact Sciences (EXAS), Exelixis (EXEL) and Halozyme Therapeutics (HALO). View all of MDGL's competitors. What other stocks do shareholders of Madrigal Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Madrigal Pharmaceuticals investors own include Achillion Pharmaceuticals (ACHN), Exelixis (EXEL), Advaxis (ADXS), Viking Therapeutics (VKTX), Sangamo Therapeutics (SGMO), Amarin (AMRN), CRISPR Therapeutics (CRSP), Intercept Pharmaceuticals (ICPT), Sarepta Therapeutics (SRPT) and Gilead Sciences (gild). What is Madrigal Pharmaceuticals' stock symbol? Madrigal Pharmaceuticals trades on the NASDAQ under the ticker symbol "MDGL." How do I buy shares of Madrigal Pharmaceuticals? Shares of MDGL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Madrigal Pharmaceuticals' stock price today? One share of MDGL stock can currently be purchased for approximately $77.35. How much money does Madrigal Pharmaceuticals make? Madrigal Pharmaceuticals (NASDAQ:MDGL) has a market capitalization of $1.32 billion. The biopharmaceutical company earns $-241,850,000.00 in net income (profit) each year or ($14.65) on an earnings per share basis. How many employees does Madrigal Pharmaceuticals have? Madrigal Pharmaceuticals employs 71 workers across the globe. When was Madrigal Pharmaceuticals founded? Madrigal Pharmaceuticals was founded in 2011. How can I contact Madrigal Pharmaceuticals? Madrigal Pharmaceuticals' mailing address is 200 BARR HARBOR DRIVE SUITE 400, WEST CONSHOHOCKEN PA, 19428. The official website for Madrigal Pharmaceuticals is www.madrigalpharma.com. The biopharmaceutical company can be reached via phone at (484) 380-9263, via email at ir@madrigalpharma.com, or via fax at 781-274-8228. This page (NASDAQ:MDGL) was last updated on 7/5/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
